Related Experiment Video
Updated: Apr 12, 2026
06:34
Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
Published on: November 29, 2024
689
Carbohydrate drugs: current status and development prospect.
1Key Laboratory of Chemical Biology of Natural Products (Ministry of Education), Institute of Biochemical and Biotechnological Drug, School of Pharmaceutical Sciences, Shandong University.
Drug Discoveries & Therapeutics
|May 22, 2015
Summary
Carbohydrate research is advancing, focusing on their biological roles and therapeutic potential. This review covers existing and emerging carbohydrate-based drugs, offering future development insights.
Area of Science:
- Biochemistry and Medicinal Chemistry
- Glycoscience and Drug Discovery
Background:
- Carbohydrates play crucial roles in biological processes.
- Significant research efforts are directed towards developing carbohydrate-based therapeutics.
Purpose of the Study:
- To review carbohydrate drugs listed in pharmacopoeias.
- To summarize marketed and investigational carbohydrate drugs.
- To discuss future prospects for carbohydrate drug development.
Main Methods:
- Literature review of pharmacopoeias.
- Analysis of marketed and clinical trial carbohydrate drugs.
- Synthesis of current research trends and future outlook.
Main Results:
- Identification of numerous carbohydrate drugs across different stages of development.
- Overview of the therapeutic areas targeted by carbohydrate drugs.
- Highlighting the growing importance of glycoscience in medicine.
Conclusions:
- Carbohydrate drugs represent a significant and expanding class of therapeutics.
- Continued research promises novel applications for carbohydrate-based medicines.
- The field of glycoscience is pivotal for future pharmaceutical innovation.
Related Concept Videos
01:26Oral Drug Delivery Systems: Continuous-Release Systems
254
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
254
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
125
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
125
01:26Targets for Drug Action: Overview
11.9K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
11.9K
01:19Modified-Release Drug Delivery Systems: Overview
192
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
192
01:29Pharmacogenomics: Identification of New Drug Targets
91
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
91
01:24Glucagon-like Receptor Agonists
1.4K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.4K